TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
EMPLOYEES
Egetis Therapeutics AB (publ)
Closing information (x1000 DKK)
| Closing information | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Turnover |
29,940
|
38,688
|
15,102 |
| Financial expenses |
19,679
|
4,635
|
468 |
| Earnings before taxes |
-222,894
|
-219,503
|
-129,504 |
| EBITDA |
-211,658
|
-215,742
|
-130,573 |
| Total assets |
514,566
|
510,607
|
374,946 |
| Current assets |
246,859
|
232,332
|
98,498 |
| Current liabilities |
132,619
|
69,787
|
33,011 |
| Equity capital |
320,118
|
366,466
|
338,260 |
| - share capital |
13,249
|
10,344
|
7,551 |
| Employees (average) |
35
|
27
|
15 |
Financial ratios
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Solvency |
62.2%
|
71.8%
|
90.2% |
| Turnover per employee |
855
|
1,433
|
1,007 |
| Profit as a percentage of turnover |
-744.5%
|
-567.4%
|
-857.5% |
| Return on assets (ROA) |
-39.5%
|
-42.1%
|
-34.4% |
| Current ratio |
186.1%
|
332.9%
|
298.4% |
| Return on equity (ROE) |
-69.6%
|
-59.9%
|
-38.3% |
| Change turnover |
-7,469
|
23,509
|
-10,453 |
| Change turnover % |
-20%
|
155%
|
-41% |
| Chg. No. of employees |
8
|
12
|
4 |
| Chg. No. of employees % |
30%
|
80%
|
36% |
Total value of public sale
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.